Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 36

1.

Influence of model-predicted rivaroxaban exposure and patient characteristics on efficacy and safety outcomes in patients with acute coronary syndrome.

Zhang L, Yan X, Nandy P, Willmann S, Fox KAA, Berkowitz SD, Sharma A, Hermanowski-Vosatka A, Schmidt S, Weitz JI, Garmann D, Peters G.

Ther Adv Cardiovasc Dis. 2019 Jan-Dec;13:1753944719863641. doi: 10.1177/1753944719863641.

2.

Enhancing the Quality of Rivaroxaban Exposure Estimates Using Prothrombin Time in the Absence of Pharmacokinetic Sampling.

Solms A, Frede M, Berkowitz SD, Hermanowski-Vosatka A, Kubitza D, Mueck W, Spiro TE, Willmann S, Yan X, Zhang L, Garmann D.

CPT Pharmacometrics Syst Pharmacol. 2019 Jul 5. doi: 10.1002/psp4.12444. [Epub ahead of print]

3.

Pharmacokinetic-pharmacodynamic studies of the 11β-hydroxysteroid dehydrogenase type 1 inhibitor MK-0916 in healthy subjects.

Wright DH, Stone JA, Crumley TM, Wenning L, Zheng W, Yan K, Yang AY, Sun L, Cilissen C, Ramael S, Hermanowski-Vosatka A, Langdon RB, Gottesdiener KM, Wagner JA, Lai E.

Br J Clin Pharmacol. 2013 Dec;76(6):917-31. doi: 10.1111/bcp.12131.

4.

11β-HSD1 inhibition reduces atherosclerosis in mice by altering proinflammatory gene expression in the vasculature.

Luo MJ, Thieringer R, Springer MS, Wright SD, Hermanowski-Vosatka A, Plump A, Balkovec JM, Cheng K, Ding GJ, Kawka DW, Koo GC, Grand CB, Luo Q, Maletic MM, Malkowitz L, Shah K, Singer I, Waddell ST, Wu KK, Yuan J, Zhu J, Stepaniants S, Yang X, Lum PY, Wang IM.

Physiol Genomics. 2013 Jan 7;45(1):47-57. doi: 10.1152/physiolgenomics.00109.2012. Epub 2012 Nov 20.

PMID:
23170035
5.

Efficacy and safety of the selective 11β-HSD-1 inhibitors MK-0736 and MK-0916 in overweight and obese patients with hypertension.

Shah S, Hermanowski-Vosatka A, Gibson K, Ruck RA, Jia G, Zhang J, Hwang PM, Ryan NW, Langdon RB, Feig PU.

J Am Soc Hypertens. 2011 May-Jun;5(3):166-76. doi: 10.1016/j.jash.2011.01.009. Epub 2011 Mar 21.

PMID:
21419745
6.

Effects of an 11β-hydroxysteroid dehydrogenase type 1 inhibitor, MK-0916, in patients with type 2 diabetes mellitus and metabolic syndrome.

Feig PU, Shah S, Hermanowski-Vosatka A, Plotkin D, Springer MS, Donahue S, Thach C, Klein EJ, Lai E, Kaufman KD.

Diabetes Obes Metab. 2011 Jun;13(6):498-504. doi: 10.1111/j.1463-1326.2011.01375.x.

PMID:
21272190
7.

Design of the DEFINE trial: determining the EFficacy and tolerability of CETP INhibition with AnacEtrapib.

Cannon CP, Dansky HM, Davidson M, Gotto AM Jr, Brinton EA, Gould AL, Stepanavage M, Liu SX, Shah S, Rubino J, Gibbons P, Hermanowski-Vosatka A, Binkowitz B, Mitchel Y, Barter P; DEFINE investigators.

Am Heart J. 2009 Oct;158(4):513-519.e3. doi: 10.1016/j.ahj.2009.07.028.

PMID:
19781408
8.

Phenylcyclobutyl triazoles as selective inhibitors of 11beta-hydroxysteroid dehydrogenase type I.

Zhu Y, Olson SH, Graham D, Patel G, Hermanowski-Vosatka A, Mundt S, Shah K, Springer M, Thieringer R, Wright S, Xiao J, Zokian H, Dragovic J, Balkovec JM.

Bioorg Med Chem Lett. 2008 Jun 1;18(11):3412-6. doi: 10.1016/j.bmcl.2008.04.014. Epub 2008 Apr 10.

PMID:
18440812
9.

4-Methyl-5-phenyl triazoles as selective inhibitors of 11beta-hydroxysteroid dehydrogenase type I.

Zhu Y, Olson SH, Hermanowski-Vosatka A, Mundt S, Shah K, Springer M, Thieringer R, Wright S, Xiao J, Zokian H, Balkovec JM.

Bioorg Med Chem Lett. 2008 Jun 1;18(11):3405-11. doi: 10.1016/j.bmcl.2008.04.013. Epub 2008 Apr 10.

PMID:
18440811
10.

Bis-aryl triazoles as selective inhibitors of 11beta-hydroxysteroid dehydrogenase type 1.

Aster SD, Graham DW, Kharbanda D, Patel G, Ponpipom M, Santorelli GM, Szymonifka MJ, Mundt SS, Shah K, Springer MS, Thieringer R, Hermanowski-Vosatka A, Wright SD, Xiao J, Zokian H, Balkovec JM.

Bioorg Med Chem Lett. 2008 May 1;18(9):2799-804. doi: 10.1016/j.bmcl.2008.04.010. Epub 2008 Apr 9.

PMID:
18434143
11.

Depot-specific regulation of the conversion of cortisone to cortisol in human adipose tissue.

Lee MJ, Fried SK, Mundt SS, Wang Y, Sullivan S, Stefanni A, Daugherty BL, Hermanowski-Vosatka A.

Obesity (Silver Spring). 2008 Jun;16(6):1178-85. doi: 10.1038/oby.2008.207. Epub 2008 Apr 3.

12.

Discovery of 4-heteroarylbicyclo[2.2.2]octyltriazoles as potent and selective inhibitors of 11beta-HSD1: novel therapeutic agents for the treatment of metabolic syndrome.

Gu X, Dragovic J, Koo GC, Koprak SL, LeGrand C, Mundt SS, Shah K, Springer MS, Tan EY, Thieringer R, Hermanowski-Vosatka A, Zokian HJ, Balkovec JM, Waddell ST.

Bioorg Med Chem Lett. 2005 Dec 1;15(23):5266-9. Epub 2005 Sep 26.

PMID:
16185866
13.

Inhibition of 11beta-HSD1 as a novel treatment for the metabolic syndrome: do glucocorticoids play a role?

Thieringer R, Hermanowski-Vosatka A.

Expert Rev Cardiovasc Ther. 2005 Sep;3(5):911-24. Review.

PMID:
16181035
14.

High-throughput screening of 11beta-hydroxysteroid dehydrogenase type 1 in scintillation proximity assay format.

Solly K, Mundt SS, Zokian HJ, Ding GJ, Hermanowski-Vosatka A, Strulovici B, Zheng W.

Assay Drug Dev Technol. 2005 Aug;3(4):377-84.

PMID:
16180992
15.
16.

An interview with Anne Hermanowski-Vosatka, M.D., Ph.D. Interview by Vicki Glaser.

Hermanowski-Vosatka A.

Assay Drug Dev Technol. 2005 Aug;3(4):363-6. No abstract available.

PMID:
16180990
17.

11beta-HSD1 inhibition ameliorates metabolic syndrome and prevents progression of atherosclerosis in mice.

Hermanowski-Vosatka A, Balkovec JM, Cheng K, Chen HY, Hernandez M, Koo GC, Le Grand CB, Li Z, Metzger JM, Mundt SS, Noonan H, Nunes CN, Olson SH, Pikounis B, Ren N, Robertson N, Schaeffer JM, Shah K, Springer MS, Strack AM, Strowski M, Wu K, Wu T, Xiao J, Zhang BB, Wright SD, Thieringer R.

J Exp Med. 2005 Aug 15;202(4):517-27.

18.

Adamantyl triazoles as selective inhibitors of 11beta-hydroxysteroid dehydrogenase type 1.

Olson S, Aster SD, Brown K, Carbin L, Graham DW, Hermanowski-Vosatka A, LeGrand CB, Mundt SS, Robbins MA, Schaeffer JM, Slossberg LH, Szymonifka MJ, Thieringer R, Wright SD, Balkovec JM.

Bioorg Med Chem Lett. 2005 Oct 1;15(19):4359-62.

PMID:
16039856
19.

Deficiency in sPLA(2) does not affect HDL levels or atherosclerosis in mice.

Burton CA, Patel S, Mundt S, Hassing H, Zhang D, Hermanowski-Vosatka A, Wright SD, Chao YS, Detmers PA, Sparrow CP.

Biochem Biophys Res Commun. 2002 May 31;294(1):88-94.

PMID:
12054745
20.

ApoE(-/-) mice develop atherosclerosis in the absence of complement component C5.

Patel S, Thelander EM, Hernandez M, Montenegro J, Hassing H, Burton C, Mundt S, Hermanowski-Vosatka A, Wright SD, Chao YS, Detmers PA.

Biochem Biophys Res Commun. 2001 Aug 10;286(1):164-70.

PMID:
11485323
21.

11 Beta-hydroxysteroid dehydrogenase type 1 is induced in human monocytes upon differentiation to macrophages.

Thieringer R, Le Grand CB, Carbin L, Cai TQ, Wong B, Wright SD, Hermanowski-Vosatka A.

J Immunol. 2001 Jul 1;167(1):30-5.

22.

Induction of 11beta-hydroxysteroid dehydrogenase type 1 but not -2 in human aortic smooth muscle cells by inflammatory stimuli.

Cai TQ, Wong B, Mundt SS, Thieringer R, Wright SD, Hermanowski-Vosatka A.

J Steroid Biochem Mol Biol. 2001 May;77(2-3):117-22.

PMID:
11377976
23.

Peroxisome proliferator-activated receptor-gamma ligands inhibit adipocyte 11beta -hydroxysteroid dehydrogenase type 1 expression and activity.

Berger J, Tanen M, Elbrecht A, Hermanowski-Vosatka A, Moller DE, Wright SD, Thieringer R.

J Biol Chem. 2001 Apr 20;276(16):12629-35. Epub 2001 Jan 22.

24.

Simvastatin has anti-inflammatory and antiatherosclerotic activities independent of plasma cholesterol lowering.

Sparrow CP, Burton CA, Hernandez M, Mundt S, Hassing H, Patel S, Rosa R, Hermanowski-Vosatka A, Wang PR, Zhang D, Peterson L, Detmers PA, Chao YS, Wright SD.

Arterioscler Thromb Vasc Biol. 2001 Jan;21(1):115-21.

PMID:
11145942
25.

PPARalpha agonists reduce 11beta-hydroxysteroid dehydrogenase type 1 in the liver.

Hermanowski-Vosatka A, Gerhold D, Mundt SS, Loving VA, Lu M, Chen Y, Elbrecht A, Wu M, Doebber T, Kelly L, Milot D, Guo Q, Wang PR, Ippolito M, Chao YS, Wright SD, Thieringer R.

Biochem Biophys Res Commun. 2000 Dec 20;279(2):330-6.

PMID:
11118287
26.

Expression of the type I diabetes-associated gene LRP5 in macrophages, vitamin A system cells, and the Islets of Langerhans suggests multiple potential roles in diabetes.

Figueroa DJ, Hess JF, Ky B, Brown SD, Sandig V, Hermanowski-Vosatka A, Twells RC, Todd JA, Austin CP.

J Histochem Cytochem. 2000 Oct;48(10):1357-68.

PMID:
10990489
27.

Deficiency in inducible nitric oxide synthase results in reduced atherosclerosis in apolipoprotein E-deficient mice.

Detmers PA, Hernandez M, Mudgett J, Hassing H, Burton C, Mundt S, Chun S, Fletcher D, Card DJ, Lisnock J, Weikel R, Bergstrom JD, Shevell DE, Hermanowski-Vosatka A, Sparrow CP, Chao YS, Rader DJ, Wright SD, Puré E.

J Immunol. 2000 Sep 15;165(6):3430-5.

28.

Infectious agents are not necessary for murine atherogenesis.

Wright SD, Burton C, Hernandez M, Hassing H, Montenegro J, Mundt S, Patel S, Card DJ, Hermanowski-Vosatka A, Bergstrom JD, Sparrow CP, Detmers PA, Chao YS.

J Exp Med. 2000 Apr 17;191(8):1437-42.

29.

Enzymatically inactive macrophage migration inhibitory factor inhibits monocyte chemotaxis and random migration.

Hermanowski-Vosatka A, Mundt SS, Ayala JM, Goyal S, Hanlon WA, Czerwinski RM, Wright SD, Whitman CP.

Biochemistry. 1999 Sep 28;38(39):12841-9.

PMID:
10504254
30.

Migration of intestinal intraepithelial lymphocytes into a polarized epithelial monolayer.

Shaw SK, Hermanowski-Vosatka A, Shibahara T, McCormick BA, Parkos CA, Carlson SL, Ebert EC, Brenner MB, Madara JL.

Am J Physiol. 1998 Sep;275(3):G584-91. doi: 10.1152/ajpgi.1998.275.3.G584.

PMID:
9724272
31.

Prediction of therapy-related acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS) after autologous bone marrow transplant (ABMT) for lymphoma.

Legare RD, Gribben JG, Maragh M, Hermanowski-Vosatka A, Roach S, Tantravahi R, Nadler LM, Gilliland DG.

Am J Hematol. 1997 Sep;56(1):45-51.

32.

Characterization of caveolin-rich membrane domains isolated from an endothelial-rich source: implications for human disease.

Lisanti MP, Scherer PE, Vidugiriene J, Tang Z, Hermanowski-Vosatka A, Tu YH, Cook RF, Sargiacomo M.

J Cell Biol. 1994 Jul;126(1):111-26.

33.

Integrin modulating factor-1: a lipid that alters the function of leukocyte integrins.

Hermanowski-Vosatka A, Van Strijp JA, Swiggard WJ, Wright SD.

Cell. 1992 Jan 24;68(2):341-52.

PMID:
1733503
34.

Activation of the adhesive capacity of CR3 on neutrophils by endotoxin: dependence on lipopolysaccharide binding protein and CD14.

Wright SD, Ramos RA, Hermanowski-Vosatka A, Rockwell P, Detmers PA.

J Exp Med. 1991 May 1;173(5):1281-6.

35.

Dynamic interactions of c-fos protein in serum-stimulated 3T3 cells.

Vosatka RJ, Hermanowski-Vosatka A, Metz R, Ziff EB.

J Cell Physiol. 1989 Mar;138(3):493-502.

PMID:
2494195
36.

Clustering of ligand on the surface of a particle enhances adhesion to receptor-bearing cells.

Hermanowski-Vosatka A, Detmers PA, Götze O, Silverstein SC, Wright SD.

J Biol Chem. 1988 Nov 25;263(33):17822-7.

Supplemental Content

Loading ...
Support Center